Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment
Version of Record online: 5 JAN 2002
Blackwell Science Ltd, 1997
Journal of Internal Medicine
Volume 244, Issue 2, pages 169–174, August 1998
How to Cite
Aarsand and Carlsen (1998), Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. Journal of Internal Medicine, 244: 169–174. doi: 10.1046/j.1365-2796.1998.00361.x
- Issue online: 5 JAN 2002
- Version of Record online: 5 JAN 2002
- vitamin B12
Aarsand AK, Carlsen SM (Norwegian University of Science and Technology, Trondheim, Norway.) Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 1998; 244: 169–74.
Metformin treatment increases circulating homocysteine levels. We studied whether administration of folate reduces serum total homocysteine levels in patients on long-term metformin treatment.
A prospective, randomized, double-blind, placebo-controlled study lasting for 12 weeks and taking place in a university hospital setting.
Thirty patients treated with a metformin dose of at least 1000 mg day−1 for a minimum of 1 year were included. At baseline serum total homocysteine levels were within the reference range. One patient who withdrew and one who died were excluded from the statistical evaluation. Twenty-six of the remaining patients suffered from NIDDM, the other two from hyperlipidaemia.
Patients were randomized into two groups at week 0. The folate group received 0.25 mg day−1 of folate in addition to 60 mg day−1 of Fe2+, while the placebo group received only 60 mg day−1 of Fe2+.
Main outcome measures
Fasting homocysteine, cysteine, cysteinylglycine, vitamin B12 and folate were measured at week 0, 4 and 12. Changes from week 0 to week 4 and from week 0 to week 12 were calculated.
Folate administration reduced serum levels of total homocysteine in the folate group as compared with the placebo group by 13.9% (P < 0.01) and 21.7% (P < 0.001) at week 4 and 12, respectively. In the folate group versus the placebo group serum levels of vitamin B12 increased by 9.9% (P= 0.010) and 9.6% (P= 0.043) while folate levels increased by 96.9 and 89.9% at week 4 and 12, respectively.
The present study indicates that the homocysteine-increasing effect of metformin can be counteracted by folate administration.